Perspectives on Patient Recruitment
|
|
- Barnaby Bridges
- 3 years ago
- Views:
From this document you will learn the answers to the following questions:
What is one place where the need is most likely to have a good chance of success?
What is the Pillars of feasibility?
What type of therapeutic area depends on the safety profile of?
Transcription
1 Webcast Perspectives on Patient Recruitment Sponsors:
2 Presenters Moderator: Christiane Truelove Editor in Chief, R&D Directions Speakers: Dr. Bradley Vince, D.O., President and Medical Director, Vince and Associates Clinical Research Jeffrey M. Zucker Senior Director and Global Head, Patient Recruitment, Kendle Kathy Chase, Pharm.D. IRB chair, MidLands IRB; Director, Provider Services, Cardinal Health Pharmacy Solutions
3 Bradley Vince, D.O. President and Medical Director 3
4 Dr. Vince has participated in over 325 clinical trials His focus is Phase 1 to Proof of Concept Dr. Vince was involved in the design and construction of their new 90 bed Early Development Unit. The objective of this new facility is enhanced recruitment of patient population trials and studies with long-term confinement periods. 4
5 5
6 Discussion Topics: Overview Finalizing the Protocol Feasibility Recruitment Medical Oversight Retention 6
7 Special populations are being enrolled earlier in the clinical trials process More Phase I trials (including FIH and MAD) are: Incorporating patient populations into the study design Often consolidating SAD/MAD/POC studies into one protocol with an adaptive design This depends on: Safety profile of the compound Therapeutic area This approach conserves development time and provides an earlier read on potential efficacy and tolerability 7
8 Early Physician Feedback Critical Ensures that: Safety measures are acceptable Execution is realistic Study populations are recruitable Quick Turn Around (1 week) from the PI or Medical Director Should be provided as a no-cost service to clients 8
9 Feasibility Assessments Speed important, but accurate feedback is more important In-depth feasibility protects against expensive rescue efforts PI involvement necessary to validate protocol feasibility at the site Additional review from clinical operations, regulatory, recruitment, lab and others minimize costly mistakes prior to study start Verify accuracy of the metrics from the site Unfortunately, sites often over-commit Always have Plan B 9
10 Considerations for Special Population Feasibility Assessments Competing trials (not just at the site but in the region) Competition from marketed drugs Subject compensation Time of year Risk Benefit Ratio Likelihood of placebo 10
11 Special Population Volunteers HNV Recruitment is more challenging Compensation is not always the priority Confinement periods are more problematic Evening call center hours are imperative Scheduling flexibility (including evenings and weekends) Usually not professional volunteers 11
12 Accountability Who is accountable at site level? Database Verify it Bigger is not always better Advertising Understand the site s plan Advertising dollars should be specific to YOUR study (not generic) If additional advertising funds are needed funds recruitment Market saturation Competing trials Skin in the game 12
13 Competition is good (multi-center studies) s, Newsletters FSFV Milestone, Most Randomized Call the PI Confirm Appointments Welcome packets and handholding Physician Referrals Beware 13
14 Special population volunteers HNV Existing medical co-morbidities Require additional medical oversight Concomitant medications AE assessment 14
15 Special population volunteers HNV More family involvement Require more personal attention of P.I. Have more medical questions 15
16 Staff (Warm and Empathetic) Meals (Hot and Tasty) Lighting (Bright with Natural Light) Dorm Size and Assignments (Room to Roam) Mattresses (Sounds Trivial) Technology (70 s, 80 s or today?) Entertainment (Wifi, Movies, How many TVs?, Activities) 16
17 Customer Service Training (Serve, Serve, Serve) Full-time Housekeeper (White-glove inspection) Bathrooms (Individual and private) Medical Safety (Highly visible nurses station) Physician Availability (That s my P.I.) Access Outdoors (Sunshine) Visitors (Welcome; but have a plan and process) Compensation (Important, but only part of the answer) 17
18 Beyond Paper Using data-driven expertise to enhance patient recruitment Jeffrey Zucker, MS Senior Director and Global Head, Patient Recruitment Kendle
19 Agenda Components to successful recruitment planning Role of Feasibility Use of internal resources Accessing external data Applying the data to simulate recruitment timelines Factoring in recruitment tactics Optimizing timelines Measuring success 19 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
20 Components Vendors Internal Expertise Feasibility Regulatory Patient Recruitment Medical Affairs Marketing Investigator Consult Key Opinion Leaders 20 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
21 Pillars of feasibility Feasibility Internal data External data Medical review and engagement Previous trials conducted database/ctms Previous experience with investigators Regulatory and contract timelines Expertise of internal staff and lesson s learned Standard of care for indication and country Competing clinical trials Disease incidence/prevalence Benchmarking/clinical trial intelligence Detailed examination of protocol medical team Identify and engage key opinion leaders as needed Develop relationships with key advocacy/support groups Internal expertise and relationships Site-specific questionnaires Validate assumptions Confirm investigator availability and build interest in trial Explore potential patient recruitment strategies 21 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
22 Internal resource Medical Medical Affairs Full review of I/E criteria Identify barriers and opportunities Study design review Burden on subject and site Compare to standard of care Comparison to past trials Identify site requirements Specialty Geography Patient access 22 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
23 Internal resource Marketing Marketing Evaluate current therapeutic market globally Opportunities for emerging markets Identify key physicians Can influence other investigators Access to prescription data Identify hot spots for med use Competitive information Pipeline information on other companies 23 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
24 Internal resource Regulatory Regulatory Regulatory timelines are often underestimated Need full review of protocol to evaluate for country requirements Various tactics are not allowed in certain countries but some are just not typically used 24 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
25 External resource KOLs and Investigator consult Key Opinion Leaders Investigator Consult Clinical protocol guidance Standard of care Medical trends Operational guidance Recruitment issues Competitive landscape 25 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
26 External resource Vendors Vendors Media buying Material development Recruitment planning Database driven outreach Prescription data Chart reviewing at sites Recruitment workshops Website design and maintenance Site selection Text messaging New services emerging daily 26 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
27 Recruitment simulation Using data to predict success
28 Timeline modeling 250 patients were enrolled in 16 months or less 50% of the time 28 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
29 Recruitment curve 250 patients were enrolled in 16 months or less 50% of the time 29 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
30 Optimizing probability of success Change country mix Different distribution of patient allocation Over allocate patients/sites Back up sites/countries Entering additional recruitment tactics Propose protocol changes Re-run the model with new assumptions 30 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
31 Measure performance During the trial, clear milestones and contingencies need to be Every program needs and after action review Identify success, failure, barriers, and opportunities Make it an official document that is engrained into the process Conduct a team meeting to review results 31 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
32 Summary Be sure to use all internal and external resources All data is helpful just be sure you know the validity and reliability Use data to support your decisions around study planning Modeling recruitment using the data is helpful to generate discussion Specific and measureable recruitment tactics Work into the model and re-run simulation Learn from experience Minimize repetition of mistakes Leverage knowledge to identify opportunities Use common sense when analyzing data and results 32 N o r t h A m e r i c a E u r o p e A s i a / P a c i f i c L a t i n A m e r i c a A f r i c a
33 IRB Considerations in Proof of Concept Trials Kathy Chase, Pharm.D. Chair, MLIRB
34 Proof of Concept Research Study Proof of principle / concept study First time in humans Target disease state
35 Basic Elements of IRB Review Protocol Informed consent form Recruiting materials Safety reports Ongoing results
36 Fundamental Responsibility of IRB Assure the rights &welfare of the subject is protected IRB membership Review process Initial review Ongoing review
37 IRB Evaluation Drug Product Experience Animal studies In vivo studies Human studies Data source
38 IRB Evaluation Research Protocol Objectives/Purpose Study Design Risk vs benefit Healthy vs disease Subject Selection Inclusion criteria Exclusion criteria
39 IRB Evaluation Research Protocol Study Methods/Procedures/Plan Diagnostic testing Dose escalation Adverse Events/Deviations Definitions Prescriptive action Evaluation Methods/Statistical Analysis
40 IRB Evaluation Informed Consent Form
41 IRB Evaluation Informed Consent Form Readability Eighth grade reading level Format
42 IRB Evaluation Informed Consent Form Purpose Easy to read The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. First time in Humans
43 IRB Evaluation Informed Consent Form Description of procedures Schedule of tests and drug administration Diagnostic tests Blood draws Frequency Amount Diaries
44 IRB Evaluation Informed Consent Form Risks Animal studies In vivo studies Human studies Similar agents
45 IRB Evaluation Informed Consent Form Risks Pregnancy risks Women Men Diagnostic test risks Psychological risks
46 IRB Evaluation Informed Consent Form Benefits Alternative Therapy
47 IRB Evaluation Subject Recruitment Vulnerable populations Children Prisoners Chronic disease Inducement IRB oversight
48 Ongoing IRB Actions Safety analysis Protocol deviations Progress reports
49 IRB Evaluation Safety Reports Serious adverse events Report to IRB IRB actions Informed consent modifications Protocol modifications FDA report Subject follow up
50 IRB Evaluation Protocol Deviations IRB review Description of deviation Intended deviation Unintended deviation IRB responsibility
51 IRB Evaluation Progress Report Frequency of Review IRB Analysis Safety Protocol deviations Audit results
52 Questions Webcast Q&A Thank you for joining us today for our webcast on Perspectives on Patient Recruitment! If you have any other questions, feel free to contact us at: Bradley Vince, D.O. President and Medical Director Rimmy Junday Account Manager Langland Quadrant Kathy Chase, Pharm.D. Chair MLIRB
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationMeeting Priorities of Biotech & Small Pharma Companies
Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,
More informationSharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,
More informationCenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
More informationTransforming study start-up for optimal results
Insight brief Transforming study start-up for optimal results A holistic, data-driven approach integrating technology, insights and proven processes to position clinical trials for ultimate success Up
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review Cindy Gates IRB Administration Tips for Reviewer s Comments - Comments should be easily transferrable
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationHow to Run Clinical Trials in Private Practice
How to Run Clinical Trials in Private Practice Thomas M. Siler, MD Midwest Chest Consultants, PC Saint Charles, MO DISCLOSURE Dr. Siler has received research grants from GlaxoSmithKline, Forest, Boehringer
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationThis policy applies to all clinical research conducted at Beaumont Health System.
CLINICAL RESEARCH QUALITY AND PROCESS IMPROVEMENT PROGRAM 113 1 of 6 PURPOSE Prior The purpose of this policy is to provide an overview of the Clinical Research Quality and Process Improvement Program
More informationPatience In Patient Recruitment
Patience In Patient Recruitment Examining Current Challenges with Humans in Phase I Clinical Trials Bryan McIntyre, Senior Vice President - Inclinix, Inc. Richard Anthony Ph D, CEO Catalyst Pharma, Inc.
More informationROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Study Start-up
More informationThe Beginner Research Assistant/Coordinator (CRC) Track Basic Level
The Beginner Research Assistant/Coordinator (CRC) Track Basic Level Who: Clinical Research Assistant (CRA) CRC I This track was designed for the CRA/CRC I with less than 2 years of clinical research experience.
More informationICH CRA Certification Guide March 2009
ICH CRA Certification Guide March 2009 ICH CRA CERTIFICATION GUIDE... 1 GENERAL INFORMATION... 2 BENEFITS OF CERTIFICATION... 2 INDUSTRY RECOGNITION... 2 ABOUT THE EXAM... 2 CRA DEFINITION... 2 REQUIREMENTS
More information2014 Metrics on Human Research Protection Program Performance
2014 Metrics on Human Research Protection Program Performance Updated May 15, 2015 About the Metrics Improving the quality of human research protection programs (HRPP) is a top priority of AAHRPP. Effective
More informationCLINICAL DEVELOPMENT OPTIMIZATION
PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP
More informationNEGOTIATING CLINICAL TRIAL BUDGETS. Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N.
NEGOTIATING CLINICAL TRIAL BUDGETS Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N. A.B.N. Amateur Budget Negotiator OVERVIEW Budget Types Analyzing the Protocol Negotiating the Contract Discussion / Tips
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationInvestigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)
March 1, 2006 M E M O R A N D U M F O R R E C O R D TO: FROM: SUBJECT: Deans Department Chairs Principal Investigators Brian Herman, Ph.D. Vice President for Research Investigator responsibilities for
More informationThe Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives
More informationYale Cancer Center Data and Safety Monitoring Committee Charter
Yale Cancer Center Data and Safety Monitoring Committee Charter Purpose/Mission The purpose of the Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) is to provide ongoing data and safety
More informationEngaging Clinical Trial Sites:
WHITE PAPER Engaging Clinical Trial Sites: The Role of the Clinical Trial Liaison Author: MARTIN LEE, MD Vice President, Global Scientific Affairs PRA Health Sciences Key Customers in Clinical Research
More informationDecember 13, 2011 Maureen Coyne
December 13, 2011 Maureen Coyne No industry relationships No financial conflicts of interests Recent experience weighted toward industrysponsored clinical trials Information based on my experiences IRB
More informationRole of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
More informationQuality Monitoring Checklist
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
More information12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
More informationOperational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
More informationEffective Strategies for Patient Recruitment and Retention. Do You Have Your Calculators Ready?
Effective Strategies for Patient Beth Harper, BS, MBA President, Clinical Performance Partners, Inc. Do You Have Your Calculators Ready? 2 CRC Best Practices 3.0 1 3 What do calculations have to do with
More informationNo. 706. Page 1 of 5. Issue Date 4/21/2014
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
More informationPHASE IIB III. inventivhealthclinical.com
PHASE IIB III inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 DATA DRIVEN, COST EFFECTIVE SOLUTIONS Feasibility Studies 03 Investigator Recruitment and Site Management 03 Patient Enrollment
More informationPREP Course #17: Are we there yet? Achieving Enrollment Success
PREP Course #17: Are we there yet? Achieving Enrollment Success Cerdi Beltre, CIP, CCRP Administrative Director, Clinical Research Service Director, Clinical Research Operations, NSLIJ 516-562-0340, cbeltre@nshs.edu
More informationStudy Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
More informationRole of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.
Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationAsk Us About Clinical Trials
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
More informationEMR Systems and the Conduct of Clinical Research. Daniel E Ford, MD, MPH Vice Dean for Clinical Investigation Johns Hopkins School of Medicine
EMR Systems and the Conduct of Clinical Research Daniel E Ford, MD, MPH Vice Dean for Clinical Investigation Johns Hopkins School of Medicine Clinical Research Environment Research protocols are becoming
More informationInnovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring
Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Brett Barber, Sr. Director, Strategic Resourcing Nicole Baker, Sr. Director, Strategic
More informationPoints to Consider When Developing a TMF (Trial Master File) Strategy
PHLEXGLOBAL WHITE PAPER Points to Consider When Developing a TMF (Trial Master File) Strategy Presented By: Karen Redding Global Business Development Director Phlexglobal Ltd. kredding@phlexglobal.com
More informationThe Evolving Role of Nurses in Early Phase Research
U.S. Department of Health and Human Services The Evolving Role of Nurses in Early Phase Research Clare Hastings, RN, PhD, FAAN Chief Nurse Officer, Clinical Center April 27, 2012 Discover America s Research
More informationthrough advances in risk-based
Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform
More informationClinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
More informationVersion history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
More informationRESEARCH STUDY PROTOCOL. Study Title. Name of the Principal Investigator
RESEARCH STUDY PROTOCOL Study Title Name of the Principal Investigator For research involving human subjects, certain elements must be included with each new IRB submission to ensure an effective review
More informationJosephine Silvestre, RN, MSN The University of Chicago Medical Center. October 13, 2007
Josephine Silvestre, RN, MSN The University of Chicago Medical Center October 13, 2007 A study in which people participate as volunteers. A clinical trial is conducted to develop potential new treatments
More informationData Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
More informationThe Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis
The Monitoring Visit Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis Disclosure The information herein is not intended to
More informationHealth Sciences Network Real-time Access To Healthcare Data for R&D Through Post Market Research
Health Sciences Network Real-time Access To Healthcare Data for R&D Through Post Market Research Joel Haspel Director Health Sciences 21, October, 2014 Safe Harbor statement The following is intended to
More informationTo Certify or Not to Certify
To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus November
More informationTo Certify or Not to Certify Sandra Halvorson, BA, CCRP
To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II We have no financial relationships
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationElectronic Medical Records and Source Data for Research: What s the Difference?
Electronic Medical Records and Source Data for Research: What s the Difference? Tammy Anderson, CCRC, CCRA, CRCP Director, Clinical Trials Office Virginia Commonwealth University Research Coordinator 4
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
More informationLeveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles
Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology Presented by: Elisa Cascade, MediGuard/Quintiles About Elisa Cascade, VP MediGuard/Quintiles Assisted in site
More informationFriday, May 2. Clinical Trials: Is Your Staff Competent? Session 10:15 11:45 am Ballroom C
Session 10:15 11:45 am Ballroom C Clinical Trials: Is Your Staff Competent? What fundamental skills and knowledge should clinical trials nurses have? In response to questions from its members about how
More informationClinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationFundamentals of Clinical Trial Financial Management
Fundamentals of Clinical Trial Financial Management Lindsey Spangler Michelle Smith COURSE OBJECTIVES Understand the life cycle of a clinical study from a financial perspective Understand the purpose of
More informationComprehensive Study Documents List (Biomedical Studies)
Comprehensive Study Documents List (Biomedical Studies) Investigators conducting human subjects research must maintain study documents in adherence to federal and state regulations, USC policies, and good
More informationRecruitment and Remuneration of Phase I Subjects May 14, 2014. Presented by: Theresa Cummings RN, MS Schulman Associates IRB
Recruitment and Remuneration of Phase I Subjects May 14, 2014 Presented by: Theresa Cummings RN, MS Schulman Associates IRB About Schulman Associates IRB Established in 1983 US and Canadian boards fully
More informationCheryl K. Bernstein RN, BSN, CCRC Director Bernstein Clinical Research Center, LLC Cincinnati, Ohio Cherylkb@fuse.net
Cheryl K. Bernstein RN, BSN, CCRC Director Bernstein Clinical Research Center, LLC Cincinnati, Ohio Cherylkb@fuse.net Identify and discuss the language used in reciprocal or crossed indemnification and
More informationSpecialty Pharmacy? Disclosure. Objectives Technician
Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University
More informationDAIDS Bethesda, MD USA POLICY. Requirements for Clinical Quality Management Plans
NOTE: This policy and associated appendices have been reviewed for accuracy and updated to meet 508 compliance guidelines. DAIDS has clearly stated the minimum requirements for the CQMP and provided examples
More informationHealth Care Job Information Sheet #20. Clinical Research
Health Care Job Information Sheet #20 Clinical Research A. Background B. Occupations 1) Clinical Research Associate (Study Monitor) 2) Clinical Research Coordinator 3) Other positions in the field C. Labour
More informationCLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]
CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
More informationWE VE WORKED WITH A DIVERSE SPONSOR BASE. HOW CAN WE HELP YOU?
Patient Recruitment & Retention Newsletter Special Points of Interest FACTORS IMPACTING ENROLLMENT RECRUITMENT INITIATIVES STUDY/ SITE OUTREACH INITIATIVES CASE STUDY JANIX International Full-Service Contract
More informationMarie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager
Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name
More informationTAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors
TAKING THE GUESSWORK OUT OF FEASIBILITY ASSESSMENT IN ONCOLOGY TRIALS Data Drives Greater Predictability, Speed and Savings for Sponsors Otis Johnson, Vice President, Clinical Research Susie Kim, Associate
More informationRECRUITMENT STRATEGIES: WAYS TO FACILITATE RESEARCH
RECRUITMENT STRATEGIES: WAYS TO FACILITATE RESEARCH PARTICIPANT ENROLLMENT AND RETENTION Rosleen Mansour, M.A. Research Coordinator Research Coordinator Department of Psychiatry and Behavioral Sciences
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationPre-Questions. Mastering Clinical Research July 29, 2015
Pre-Questions Mastering Clinical Research July 29, 2015 1. To be compliant with SOP 2.1 Obtaining Informed Consent for greater than minimal risk interventional clinical trial, which Licensed Professional
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationThe role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations
The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations Maria Luisa Paoloni OPBG Clinical & Research Services Monitoring and Responsible of monitoring:
More informationCLINICAL RESEARCH GENERIC TASK DESCRIPTIONS
Purpose Purpose Purpose Primary responsibility for implementation, coordination, evaluation, communication and/or management of research studies. May involve more than one study or multiple sites within
More informationEvaluating the impact of REMS on burden and patient access
Evaluating the impact of REMS on burden and patient access Doris Auth, Pharm.D. Team Leader, Division of Risk Management Office of Medication Error Prevention and Risk Management Center for Drug Evaluation
More informationCore Training Outline
Core Training Outline Modules: 1) Study Design 2) PI Oversight 3) Financial Management 4) Study Operations 5) Recruitment & Retention 6) Informed Consent 7) Investigational Products 8) Subject Safety 9)
More informationNavigating the Rules of Engagement In-House Counsel Perspective. Rebecca D. Prince Bristol-Myers Squibb January 21, 2015
Navigating the Rules of Engagement In-House Counsel Perspective Rebecca D. Prince Bristol-Myers Squibb January 21, 2015 1 HYPOTHETICAL CASE STUDY Biopharma Company is studying an investigational compound
More informationGuidance on IRB Continuing Review of Research
NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationHow To Manage Change
Change Management Workshop Overview Part 1 July 24, 2013 1 Start With The Final Word You don t manage change.. You must lead change! 2 Safety Message Traits of a Healthy Nuclear Safety Culture; Leadership
More informationEHR4CR ENABLING PROACTIVE RESEARCH
EHR4CR ENABLING PROACTIVE RESEARCH Neelam Patel Neelam Consulting Electronic Health Records for Clinical Research 76 Why change how I currently operate? To more visible to the clinical trial community
More informationINTERIM SITE MONITORING PROCEDURE
INTERIM SITE MONITORING PROCEDURE 1. PURPOSE The purpose of this SOP is to describe the interim monitoring procedures conducted at Institution, according to GCP and other applicable local regulations.
More informationM Matters: What s (Social) Marketing and Media Got to Do with It?
M Matters: What s (Social) Marketing and Media Got to Do with It? Pattie Yu Karen Waller GYMR Public Relations Washington, DC www.gymr.com October 4, 2007 Why Social Marketing? Use the principles of marketing
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationCNE Disclosures. To change this title, go to Notes Master
CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion
More informationCLINICAL RESEARCH PROTOCOL CHECKLIST
CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationSection 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership
Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership PROJECT MANAGEMENT - SCOPE DEFINITION AND MANAGEMENT Understands the
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationPrincipal Investigator Responsibilities for Education and Social/Behavioral Researchers
Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Introduction The purpose of this module is to provide a basic understanding of the responsibilities of the principal
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
More information